Total: 6244

Situação epidemiológica atual - 14 de outubro de 2020

O boletim descreve de forma detalhada a situação da COVID-19 no Estado da Bahia desde o inicio da pandemia. Contempla informações relacionadas ao registro de casos notificados da COVID-19, taxa de crescimento, distribuição de casos confirmados nos Núcleos Regionais Saúde, casos confirmados segund...

Situação epidemiológica (04/02 a 10/10/2020)

Esta edição do Boletim Epidemiológico COVID19 apresenta um panorama geral desde os primeiros registros na China em dezembro de 2019 até o dia 10 de outubro foram confirmados 37.109.851 casos de COVID-19 no mundo. Deste total, 1.070.355 evoluíram a óbito. Quando comparados o número de casos e óbit...

Clinical outcomes according to lesion complexity in patients with high bleeding risk treated with 1-month dual antiplatelet therapy following pci: analysis from the onyx one clear study

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND Safety and effectiveness outcomes were examined at 1 year among high bleeding risk (HBR) patients treated with 1 month of dual antiplatelet therapy (DAPT) following PCI with zotarolimus eluting stents (ZES) (Resolute Onyx, Medtronic, Santa Rosa, Califor nia) according to lesion complexity (Tab...

Ischemic and bleeding outcomes in patients with versus without atrial fibrillation: analysis from the onyx one month dapt program

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND The Onyx ONE and Onyx ONE CLEAR studies demonstrated favorable safety and effectiveness in patients at high bleeding risk (HBR) who were event-free 1 month following Resolute Onyx zotarolimus-eluting stent (ZES) implantation and were then treated with single antiplatelet therapy (SAPT) through...

FANTOM II Trial: safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffolddfirst report: 4-year clinical outcomes

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND The primary objective of the FANTOM II (Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold) was to evaluate the safety and performance of native coronary artery stenting using the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold by assessing th...

The MeRes-1 Extend Trial: 2-year clinical and 6-month imaging outcomes of thin-strut sirolimus-eluting brs in patients with de novo coronary artery lesions

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND The long- term clinical outcomes of percutaneous coronary intervention can be improved by replacing metallic drug eluting stents with bioresorbable vascular scaffolds. The MeRes-1 Extend trial was designed to assess the safety and efficacy of a novel thin-strut MeRes100 bioresorbable vascular ...

Sirolimus Eluting, tyrocore, bioresorbable vascular scaffold implantation in patients with st-segment elevation myocardial infarction: 12 month outcomes-FANTOM STEMI pilot study

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND The objective of this study is to evaluate safety and performance of the Fantom bioresorbable coronary scaffold in the acute setting of myocardial infarction with unstable lesions and thrombogenic milieu. Fantom (Tyrocore, REVA Medical) is composed mainly of an iodinated, polycarbonate copolym...

Situação epidemiológica atual - 13 de outubro de 2020

O boletim descreve de forma detalhada a situação da COVID-19 no Estado da Bahia desde o inicio da pandemia. Contempla informações relacionadas ao registro de casos notificados da COVID-19, taxa de crescimento, distribuição de casos confirmados nos Núcleos Regionais Saúde, casos confirmados segund...

Situação epidemiológica atual - 12 de outubro de 2020

Boletim infográfico com o panorama da situação da pandemia COVID-19 em 12/10/2020, contempla informações sobre a distribuição de casos confirmados e número de óbitos no mundo, Brasil e na Bahia. Com relação ao Estado da Bahia apresenta detalhamento sobre: dados laboratoriais de COVID-19; porce...